Akili (NASDAQ:AKLI – Get Free Report) is one of 222 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it compare to its competitors? We will compare Akili to similar companies based on the strength of its analyst recommendations, valuation, profitability, earnings, institutional ownership, risk and dividends.
Insider & Institutional Ownership
52.8% of Akili shares are held by institutional investors. Comparatively, 44.4% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 20.4% of Akili shares are held by insiders. Comparatively, 13.8% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Akili and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Akili | 940.71% | -72.28% | -54.30% |
| Akili Competitors | -616.34% | -308.85% | -28.56% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Akili | 0 | 2 | 4 | 0 | 2.67 |
| Akili Competitors | 1262 | 3920 | 8111 | 203 | 2.54 |
Akili currently has a consensus price target of $3.50, indicating a potential upside of 268.42%. As a group, “Surgical & medical instruments” companies have a potential upside of 38.84%. Given Akili’s stronger consensus rating and higher possible upside, equities analysts clearly believe Akili is more favorable than its competitors.
Risk and Volatility
Akili has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Akili’s competitors have a beta of 1.34, meaning that their average share price is 34% more volatile than the S&P 500.
Valuation and Earnings
This table compares Akili and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Akili | $420,000.00 | -$7.96 million | -6.79 |
| Akili Competitors | $1.18 billion | $58.67 million | 29.37 |
Akili’s competitors have higher revenue and earnings than Akili. Akili is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
Akili beats its competitors on 7 of the 13 factors compared.
About Akili
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. Akili, Inc. was founded in 2011 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Akili Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akili and related companies with MarketBeat.com's FREE daily email newsletter.
